IL246931B - Solid forms of 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxyamide, their compositions and methods of using them - Google Patents

Solid forms of 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxyamide, their compositions and methods of using them

Info

Publication number
IL246931B
IL246931B IL246931A IL24693116A IL246931B IL 246931 B IL246931 B IL 246931B IL 246931 A IL246931 A IL 246931A IL 24693116 A IL24693116 A IL 24693116A IL 246931 B IL246931 B IL 246931B
Authority
IL
Israel
Prior art keywords
methylcyclohexylamino
butylamino
carboxamide
pyrimidine
tert
Prior art date
Application number
IL246931A
Other languages
English (en)
Hebrew (he)
Other versions
IL246931A0 (en
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53678405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL246931(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of IL246931A0 publication Critical patent/IL246931A0/en
Publication of IL246931B publication Critical patent/IL246931B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL246931A 2014-01-30 2016-07-25 Solid forms of 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxyamide, their compositions and methods of using them IL246931B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933636P 2014-01-30 2014-01-30
US201462025161P 2014-07-16 2014-07-16
PCT/US2015/013412 WO2015116755A2 (en) 2014-01-30 2015-01-29 Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use

Publications (2)

Publication Number Publication Date
IL246931A0 IL246931A0 (en) 2016-09-29
IL246931B true IL246931B (en) 2020-06-30

Family

ID=53678405

Family Applications (2)

Application Number Title Priority Date Filing Date
IL246931A IL246931B (en) 2014-01-30 2016-07-25 Solid forms of 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxyamide, their compositions and methods of using them
IL275305A IL275305B (en) 2014-01-30 2020-06-11 Solid forms of 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxyamide, their compositions and methods of using them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL275305A IL275305B (en) 2014-01-30 2020-06-11 Solid forms of 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxyamide, their compositions and methods of using them

Country Status (32)

Country Link
US (7) US9365524B2 (enExample)
EP (2) EP3099302B1 (enExample)
JP (3) JP2017504632A (enExample)
KR (2) KR102760889B1 (enExample)
CN (3) CN106163523A (enExample)
AU (2) AU2015211036B2 (enExample)
BR (2) BR122020003206B1 (enExample)
CA (1) CA2938187C (enExample)
CL (1) CL2016001927A1 (enExample)
CR (1) CR20160346A (enExample)
CY (1) CY1123267T1 (enExample)
DK (1) DK3099302T3 (enExample)
EA (2) EA031671B1 (enExample)
ES (1) ES2811834T3 (enExample)
HR (1) HRP20201244T1 (enExample)
HU (1) HUE051266T2 (enExample)
IL (2) IL246931B (enExample)
LT (1) LT3099302T (enExample)
MX (3) MX373804B (enExample)
MY (1) MY180020A (enExample)
NZ (3) NZ715903A (enExample)
PE (1) PE20161437A1 (enExample)
PH (1) PH12016501472B1 (enExample)
PL (1) PL3099302T3 (enExample)
PT (1) PT3099302T (enExample)
RS (1) RS60715B1 (enExample)
SA (1) SA516371578B1 (enExample)
SG (1) SG11201606054SA (enExample)
SI (1) SI3099302T1 (enExample)
SM (1) SMT202000430T1 (enExample)
TW (1) TWI631108B (enExample)
WO (1) WO2015116755A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI548621B (zh) 2011-04-22 2016-09-11 標誌製藥公司 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
NZ715903A (en) * 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
EP3712134B1 (en) 2014-12-16 2023-11-29 Signal Pharmaceuticals, LLC Salts of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
US9513297B2 (en) 2014-12-16 2016-12-06 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
EP3325432B1 (en) 2015-07-24 2020-09-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
CN111934089B (zh) 2019-05-13 2021-10-26 华为技术有限公司 天线装置及移动终端
CN113698408B (zh) * 2020-05-22 2025-07-25 武汉朗来科技发展有限公司 Jnk抑制剂、其药物组合物和用途

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH549339A (de) 1971-05-12 1974-05-31 Ciba Geigy Ag Herbizides mittel.
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5852028A (en) * 1995-12-18 1998-12-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5811428A (en) * 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
ATE401312T1 (de) 1997-12-15 2008-08-15 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
EP1184376B1 (en) 1999-06-09 2005-02-02 Yamanouchi Pharmaceutical Co. Ltd. Novel heterocyclic carboxamide derivatives
AU5108000A (en) 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003082855A1 (en) 2002-03-28 2003-10-09 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
ES2373226T3 (es) * 2002-06-28 2012-02-01 Astellas Pharma Inc. Derivado de diaminopirimidincarboxamida.
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
US20040185429A1 (en) * 2002-12-09 2004-09-23 Judith Kelleher-Andersson Method for discovering neurogenic agents
JPWO2004054617A1 (ja) 2002-12-13 2006-04-20 協和醗酵工業株式会社 中枢疾患の予防および／または治療剤
EP1590334B1 (en) 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
ATE542801T1 (de) 2003-08-15 2012-02-15 Novartis Ag Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
JP2007506746A (ja) 2003-09-24 2007-03-22 ワイス・ホールディングズ・コーポレイション 抗癌剤としての５−アリールピリミジン類
WO2005095382A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 抗腫瘍剤
US7601714B2 (en) 2004-07-08 2009-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
CA2579007A1 (en) 2004-09-10 2006-03-16 Altana Pharma Ag Ciclesonide and syk inhibitor combination and methods of use thereof
JP2008512429A (ja) 2004-09-10 2008-04-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング ロフルミラストとｓｙｋインヒビターとの組合せ物並びにその使用方法
ATE542802T1 (de) 2004-09-30 2012-02-15 Tibotec Pharm Ltd Hiv-inhibierende 5-substituierte pyrimidine
JP2006124387A (ja) 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
EP1858882A1 (en) 2005-03-10 2007-11-28 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
WO2008009458A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
US20080139531A1 (en) 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
DK2146779T3 (en) 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
JP2010525047A (ja) 2007-04-27 2010-07-22 アストラゼネカ アクチボラグ 増殖状態の処置のためのＥｐｈＢ４キナーゼ阻害剤としてのＮ’−（フェニル）−Ｎ−（モルホリン−４−イル−ピリジン−２−イル）−ピリミジン−２，４−ジアミン誘導体
CN101796046A (zh) 2007-07-16 2010-08-04 阿斯利康(瑞典)有限公司 嘧啶衍生物934
CN101903357A (zh) 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
CA2723205C (en) * 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
KR20100132550A (ko) 2008-04-16 2010-12-17 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
BRPI0910668A2 (pt) 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc inibidores de proteína quinases
JP2011523646A (ja) 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
EP2325175A4 (en) 2008-09-01 2012-03-21 Astellas Pharma Inc 2,4-DIAMINOPYRIMIDINVERBINDUNG
BRPI0918045A2 (pt) 2008-09-18 2015-12-01 Astellas Pharma Inc compostos de carboxamida heterocíclicos
TW201016676A (en) 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
EP2346988B1 (en) 2008-10-31 2017-05-31 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
JP5683489B2 (ja) 2009-01-12 2015-03-11 アレイ バイオファーマ、インコーポレイテッド ピペリジン含有化合物およびその用途
CA2749403A1 (en) * 2009-01-13 2010-09-02 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
WO2010090875A1 (en) 2009-01-21 2010-08-12 Rigel Pharmaceuticals, Inc. Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
WO2010129802A1 (en) * 2009-05-06 2010-11-11 Portola Pharmaceuticals, Inc. Inhibitors of jak
MX2011011875A (es) * 2009-05-08 2011-12-08 Astellas Pharma Inc Compuesto de carboxamida heterociclica diamino.
MX2011013325A (es) 2009-06-10 2012-04-30 Abbott Lab 2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.
JP2012197231A (ja) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
WO2011065800A2 (ko) 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
US20110130415A1 (en) 2009-12-01 2011-06-02 Rajinder Singh Protein kinase c inhibitors and uses thereof
CA2801781C (en) 2010-07-21 2018-02-27 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
US8580805B2 (en) * 2010-08-31 2013-11-12 Hubert Maehr Pyrimidine carboxamide derivatives
WO2012044936A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
WO2012045020A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
TWI548621B (zh) * 2011-04-22 2016-09-11 標誌製藥公司 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
US9321763B2 (en) * 2012-04-04 2016-04-26 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
EP2928891B1 (en) * 2012-12-04 2019-02-20 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
US9169249B2 (en) * 2013-03-14 2015-10-27 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
WO2015039613A1 (zh) * 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
RU2016129380A (ru) * 2013-12-20 2018-01-25 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Замещенные диаминопиримидильные соединения, их композиции и способы лечения с их участием
NZ715903A (en) * 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
EP3712134B1 (en) * 2014-12-16 2023-11-29 Signal Pharmaceuticals, LLC Salts of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
EP3250557B1 (en) * 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide

Also Published As

Publication number Publication date
KR102760889B1 (ko) 2025-02-03
IL275305A (en) 2020-07-30
MX2016009989A (es) 2017-02-20
EA036964B1 (ru) 2021-01-20
AU2020202146A1 (en) 2020-04-16
SI3099302T1 (sl) 2020-10-30
US20190167678A1 (en) 2019-06-06
HUE051266T2 (hu) 2021-03-01
EA201691544A1 (ru) 2017-01-30
PL3099302T3 (pl) 2021-03-08
LT3099302T (lt) 2020-09-10
EP3099302A2 (en) 2016-12-07
CN106163523A (zh) 2016-11-23
KR20220051440A (ko) 2022-04-26
EP3099302B1 (en) 2020-06-17
MY180020A (en) 2020-11-19
PE20161437A1 (es) 2017-01-07
AU2020202146B2 (en) 2021-11-18
KR20160113269A (ko) 2016-09-28
KR102505677B1 (ko) 2023-03-03
JP2019142893A (ja) 2019-08-29
PT3099302T (pt) 2020-08-27
TWI631108B (zh) 2018-08-01
MX2019005715A (es) 2019-08-12
EA201792281A1 (ru) 2018-03-30
MX2020003173A (es) 2022-03-30
MX373804B (es) 2020-03-24
BR122020003206B1 (pt) 2023-02-07
US20150210650A1 (en) 2015-07-30
JP2020183437A (ja) 2020-11-12
AU2015211036A1 (en) 2016-08-11
NZ629885A (en) 2016-04-29
US9814713B2 (en) 2017-11-14
RS60715B1 (sr) 2020-09-30
US20200078359A1 (en) 2020-03-12
MX391127B (es) 2025-03-21
PH12016501472A1 (en) 2016-08-22
DK3099302T3 (da) 2020-08-24
EA031671B1 (ru) 2019-02-28
EP3099302A4 (en) 2017-10-04
CL2016001927A1 (es) 2017-02-24
IL246931A0 (en) 2016-09-29
NZ715903A (en) 2017-06-30
PH12016501472B1 (en) 2019-05-31
HRP20201244T1 (hr) 2020-11-13
US20160256459A1 (en) 2016-09-08
AU2015211036B2 (en) 2020-05-21
US10517873B2 (en) 2019-12-31
WO2015116755A2 (en) 2015-08-06
NZ761068A (en) 2023-02-24
BR112016017776A2 (pt) 2017-08-08
IL275305B (en) 2021-12-01
CA2938187C (en) 2022-08-09
US20180028534A1 (en) 2018-02-01
US10226461B2 (en) 2019-03-12
SA516371578B1 (ar) 2019-09-01
CN113717110A (zh) 2021-11-30
WO2015116755A3 (en) 2015-11-12
US20220378785A1 (en) 2022-12-01
CY1123267T1 (el) 2021-12-31
CN113717109A (zh) 2021-11-30
TW201615627A (zh) 2016-05-01
WO2015116755A8 (en) 2016-09-22
JP7317768B2 (ja) 2023-07-31
SMT202000430T1 (it) 2020-09-10
BR112016017776A8 (pt) 2020-06-30
US20250000860A1 (en) 2025-01-02
US11241430B2 (en) 2022-02-08
JP2017504632A (ja) 2017-02-09
SG11201606054SA (en) 2016-08-30
CA2938187A1 (en) 2015-08-06
JP6742466B2 (ja) 2020-08-19
EP3738954A1 (en) 2020-11-18
ES2811834T3 (es) 2021-03-15
CR20160346A (es) 2016-11-23
US9365524B2 (en) 2016-06-14
NZ722412A (en) 2022-10-28

Similar Documents

Publication Publication Date Title
IL275305B (en) Solid forms of 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxyamide, their compositions and methods of using them
IL257307B (en) Engineered crispr-cas9 compositions and methods of use
IL252900A0 (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
IL277814A (en) Automatic preparations containing cyclobenzaprine hydrochloride and methods for their preparation
IL260124A (en) Compounds and methods for reducing tau expression
EP3212226A4 (en) Compositions and methods of use for treating metabolic disorders
EP3174894A4 (en) Compositions and methods of use for treating metabolic disorders
HUE056172T2 (hu) Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra
SI3102555T1 (sl) Sestavki spojin in njihove uporabe
SG11201708114SA (en) Ophthalmic compositions and methods of use therefor
EP3250557A4 (en) Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
ZA201801214B (en) Compositions and methods for treatment of stroke and other cns disorders
SG11201803284YA (en) Novel method of use and compositions
EP3110435A4 (en) Methods and compositions for the delayed treatment of stroke
EP3280406A4 (en) COMPOSITIONS AND METHODS FOR TREATING MOVEMENT DISORDERS
ZA201704927B (en) Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide,compositions thereof and methods of their use
IL247645A0 (en) Preparations of seleno-organic compounds and methods of using them
HK1241726A1 (en) Eutectic formulations of cyclobenzaprine hydrochloride

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed